AlphAIAlphAI — Financial news for AI agents
investing.comNOV 32 min read$CORT

Corcept Therapeutics falls on guidance despite earnings beat

Corcept Therapeutics (CORT) reported Q3 earnings of $1.01 per share, beating estimates by $0.22, and revenue of $340.5M, up 64% YoY. Despite the beat, shares fell 3.9% due to unchanged full-year guidance. Revenue growth was driven by Korlym and Lifyorli. The company expects a decision on its relacorilant NDA by December 17, 2026.

Original reporting
investing.com
Published Nov 3, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CORT
Bearish
high confidence
Mentioned
$CORT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CORTBearishHigh
01

Why it matters

Guidance disappointment triggered a 3.9% after‑hours decline, suggesting investors prioritize forward outlook over near‑term beat.

02

Market read

The earnings release provides fresh guidance that could reshape short‑term price action for CORT and influence sentiment toward similar niche biotech stocks.

03

What to watch

Positive trial data for the BELLA Part A study and upcoming NDA filing for relacorilant may provide upside catalysts beyond the short‑term guidance miss.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Corcept Therapeutics (NASDAQ:CORT) posted Q3 2026 results with EPS $1.01 vs $0.79 consensus and revenue $340.5 M vs $323.9 M estimate, but maintained FY revenue guidance of $1.1‑$1.2 B, slightly above consensus.

Company-level read

Ticker impact

$CORTBearishHigh confidence
Context

Corcept Therapeutics reported Q3 earnings beat but its full-year revenue guidance disappointed investors, causing a 3.9% after‑hours share decline.

Expected impact

downward pressure as the market prices in the weaker revenue outlook

Evidence & confidence

Guidance below expectations is a material catalyst; the stock already fell 3.9% after‑hours, indicating immediate sell pressure.

Market effects

Sector

The biotech/endocrinology sector may see modest re‑rating as investors reassess revenue forecasts for niche hormone‑therapy companies.

Regional

U.S. biotech stocks could experience slight pullback in early trading as the news filters through.

Global

Limited; impact confined to U.S. listed specialty pharma peers.

Counterpoint

What could challenge this read

The earnings beat and strong cash position could support a bounce if the market overreacts to guidance.

Key entities

  • company
    Corcept Therapeutics

    Biopharma focused on endocrinology and oncology therapies.

  • executive
    Joseph K. Belanoff, MD

    CEO of Corcept Therapeutics, provided commentary on product uptake.

Read at source← All news

StoryCorcept Therapeutics posts Q3 earnings beat, keeps 2026 revenue guidance and awaits FDA decision

Also covered by

3 outlets

Related articles

NOV 4
$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.

finance.yahoo.com3 min
NOV 3
$CORTHighAI 8/10

Corcept’s (NASDAQ:CORT) Q3 2026: beats on revenue

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $340.5M, up 64% YoY and 1.9% above estimates. EPS of $1.01 beat estimates by 27.2%. The company reconfirmed its full-year revenue guidance of $1.15B. Operating margin improved to 33.7% YoY. CEO highlights growth in endocrinology and ovarian cancer treatments.

finance.yahoo.com2 min
NOV 3
$CORTMed

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

CORCEPT THERAPEUTICS INC (CORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update • Revenue of $340.5 million, a 64 percent increase over the same period in 2025 ◦ Korlym ® and authorized generic product revenue of $249.1 million ◦ Lifyorli ® product reven

SEC EDGAR 8-K2 min